Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Kangtai Biological's Stock Price Rises 12-Fold Following Shenzhen IPO

publication date: Mar 16, 2017
Shenzhen Kangtai Biological Products, a vaccine company, raised a modest $20 million six weeks ago in an IPO on the Shenzhen Chi-Next Exchange. The initial reaction in public trading was similarly subdued, but in the six weeks since then, Kangtai's stock price has climbed steadily, rising from its offering quote of 3.29 RMB to 40.51 RMB today -- a 12-fold return in under a month and a half. Its Chairman, Weimin Du, who owns 56% of the company, is now a China biotech billionaire, his holdings in the company worth $1.3 billion. More details....

Stock Symbol: (SHZ: 300601)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital